



**FemmePharma**  
GLOBAL HEALTHCARE, INC.

## **FEMMEPHARMA, INC. ADDS CAROLYN d'ARVILLE, MS, Ph.D. and LISA RARICK, MD, FACOG TO SCIENTIFIC ADVISORY BOARD**

November 10, 2003 WAYNE, PA – FemmePharma, Inc., a prescription pharmaceutical company dedicated to developing drugs for diseases and disorders disproportionately affecting women, proudly announces the recent addition of two new Scientific Advisory Board (SAB) members who are considered leaders in their respective fields – Drs. Carolyn d'Arville and Lisa Rarick.

"FemmePharma is pleased to have these two outstanding women join our SAB. We look forward to their guidance, expertise and contributions as we continue our pipeline development and corporate growth," said Gerianne Tringali DiPiano, the Company's President and CEO.

Dr. d'Arville is Associate Director of the Jefferson Center, Thomas Jefferson University Medical School, where she also coordinates the activities of the Ben Franklin Innovation Center. She is co-founder of the Regional Biotechnology Council serving early-stage and emerging biotech in the South Eastern Pennsylvania region. In addition, as President/Founder of Competitive Edge Technologies Inc, she combines her scientific expertise and academic knowledge to the assessment and management of companies' life science portfolios, particularly those in women's reproductive health. Previously, she joined Johnson & Johnson, Inc. where she initiated, developed and managed several feasibility projects and early stage research efforts in various arenas. Educated in the UK, Dr. d'Arville attained her MS in Virology at the University of Reading and her Ph.D. in Reproductive Endocrinology at the Welsh National School of Medicine, Wales. Her postdoctoral research included gynecologic oncology, cell and molecular biology programs.

Dr. d'Arville champions the entrepreneurial spirit embodied by FemmePharma.

"That is why FemmePharma is so intriguing to me. I admire Gerianne's tenacity – recognizing a need in women's healthcare – and doing something about it!" she said. "I look forward to contributing to FemmePharma's future and to keeping the company at the forefront of women's healthcare."

Tringali DiPiano is also pleased to have Dr. d'Arville join her team.

"We are excited about having Carolyn's expertise on our SAB, particularly as we explore and develop new technologies for treatment and drug delivery," said Tringali DiPiano.

Dr. Lisa Rarick is the former Medical Officer in the U.S. Food and Drug Administration Office of Women's Health (OWH). Dr. Rarick worked in the Center for Drug Evaluation and Research (CDER), where she reviewed and had responsibility for the management of

■ 37 West Avenue • Second Floor  
■ Wayne, Pennsylvania 19087  
■ Tel: 610.995.0801  
■ Fax: 610.995.0825

products for a wide variety of reproductive and urologic health issues including contraception, hormone therapy in both men and women, infertility and endometriosis. Dr. Rarick received her M.D. degree from the Loma Linda University School of Medicine. She completed her residency at Georgetown University School of Medicine, Department of Obstetrics and Gynecology.

"I look forward to working with the team members at FemmePharma as they move their products through clinical development toward product launch," said Dr. Rarick.

Tringali DiPiano believes Dr. Rarick's knowledge will benefit FemmePharma.

"With her strong background in women's health and her experience with the FDA, Lisa will provide FemmePharma with a valuable resource in accomplishing key milestones, such as the launch of our products to women who suffer from these diseases," Tringali-DiPiano stated.

Drs. d'Arville and Rarick join FemmePharma's current SAB members, who include Dr. Paul Dmowski, Dr. Tom Janicki, Dr. Sheldon Segal and Dr. Jerome Strauss, who serves as Chairperson.

#### **About FemmePharma**

FemmePharma was founded by Gerianne Tringali-DiPiano in 1996 to target needs within the estimated \$35 billion women's healthcare pharmaceutical market. The company is preparing for its Phase III trial for its first drug, a new treatment for endometriosis, and its Phase II trial for its drug to treat female urinary incontinence. FemmePharma is devoted to developing safe and effective drugs that minimize or eliminate unpleasant side effects associated with many medications by designing them in a manner that is specifically suited to a woman's physiology, with an eye toward the changing needs of women throughout their lives. The company has a number of drugs in development based on its proprietary technologies, including new therapeutic options for fibrocystic breast disease and the prevention of HIV/STD transmission. For more information about FemmePharma, please visit its website at [www.fpghc.com](http://www.fpghc.com).

###